Ownership and insider activity for Palvella Therapeutics, Inc. (PVLA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations.
Price
| Price | $151.43 |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-11 | JENKINS GEORGE M | S-Sale | 6,520 | $982K |
| 2026-09-11 | JENKINS GEORGE M | S-Sale | 4,577 | $694K |
| 2026-09-11 | JENKINS GEORGE M | S-Sale | 1,274 | $195K |
| 2026-09-14 | JENKINS GEORGE M | S-Sale | 5,632 | $853K |
| 2026-09-14 | JENKINS GEORGE M | S-Sale | 6,160 | $937K |
| 2026-09-14 | JENKINS GEORGE M | S-Sale | 1,560 | $239K |
| 2026-09-15 | JENKINS GEORGE M | S-Sale | 954 | $143K |
| 2026-09-15 | JENKINS GEORGE M | S-Sale | 263 | $40K |
| 2026-09-15 | JENKINS GEORGE M | S-Sale | 560 | $85K |
| 2026-09-02 | KIRITSY CHRISTOPHER P | M-Exempt | 313 | $40K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $70.4M | $117.8M | $16.1M | $7.3M | $83.6M | $58.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.7M | $3.3M | 0 | 0 | $2.3M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $75.7M | $127.6M | $16.5M | $7.5M | $88.2M | $59.0M |
| Property, Plant & Equipment | $26.0M | $23.0M | 0 | 0 | 0 | $572000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $105.0M | $153.6M | $16.5M | $7.5M | $88.2M | $59.6M |
| Accounts Payable | $1.8M | $8.6M | $3.2M | $936000 | $4.6M | $4.6M |
| Short-term Debt | $1.0M | $1.0M | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $22.1M | $50.6M | $5.8M | $2.4M | $12.0M | $11.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $431000 |
| Total Liabilities | $74.0M | $102.8M | $39.7M | $11.4M | $25.6M | $31.6M |
| Retained Earnings | -$211.4M | -$257.1M | -$95.0M | -$76.3M | -$93.7M | -$135.4M |
| Total Equity | $31.0M | $50.8M | -$23.2M | -$3.9M | $62.6M | $28.0M |
| Total Debt | $17.0M | $14.9M | 0 | 0 | 0 | $633000 |
| Net Debt | -$53.5M | -$102.9M | -$16.1M | -$7.3M | -$83.6M | -$57.3M |
| Working Capital | $53.6M | $77.1M | $10.7M | $5.2M | $76.2M | $47.6M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 5.20 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 18.02 |
Profitability
| Return on Equity | -149.07% |
| Return on Invested Capital | -79.73% |
| Return on Assets | -70.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABUS · EYPT · GHRS · KURA · NBTX · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of PVLA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks